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Many positive-strand RNA viruses encode genes that can function in trans, whereas other
genes are required in cis for genome replication. The mechanisms underlying trans- and
cis-preferences are not fully understood. Here, we evaluate this concept for hepatitis C
virus (HCV), an important cause of chronic liver disease and member of the Flaviviridae fam-
ily. HCV encodes five nonstructural (NS) genes that are required for RNA replication. To
date, only two of these genes, NS4B and NS5A, have been trans-complemented, leading to
suggestions that other replicase genes work only in cis. We describe a new quantitative sys-
tem to measure the cis- and trans-requirements for HCV NS gene function in RNA replica-
tion and identify several lethal mutations in the NS3, NS4A, NS4B, NS5A, and NS5B genes
that can be complemented in trans, alone or in combination, by expressing the NS3–5B
polyprotein from a synthetic mRNA. Although NS5B RNA binding and polymerase activities
can be supplied in trans, NS5B protein expression was required in cis, indicating that NS5B
has a cis-acting role in replicase assembly distinct from its known enzymatic activity. Fur-
thermore, the RNA binding and NTPase activities of the NS3 helicase domain were required
in cis, suggesting that these activities play an essential role in RNA template selection. A
comprehensive complementation group analysis revealed functional linkages between
NS3-4A and NS4B and between NS5B and the upstream NS3–5A genes. Finally, NS5B po-
lymerase activity segregated with a daclatasvir-sensitive NS5A activity, which could explain
the synergy of this antiviral compound with nucleoside analogs in patients. Together, these
studies define several new aspects of HCV replicase structure-function, help to explain the
potency of HCV-specific combination therapies, and provide an experimental framework for
the study of cis- and trans-acting activities in positive-strand RNA virus replication
more generally.
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Author Summary
RNA viruses encode one or more proteins that form an RNA replicase, which serves to
propagate the viral RNA genome. Some replication genes can function in trans, meaning
that proteins expressed by one viral genome can complement and assist in the replication
of a defective mutant virus within the same cell. Other viral genes work in cis, meaning
that they are unable to complement defective mutants; these cis-acting genes therefore link
the replication of a viral RNA genome to its translation. Because genetic complementation
reflects the formation of molecular interactions that were previously absent or nonfunc-
tional, understanding the cis- and trans-activities of viral replication proteins can provide
insights into the structure and function of viral replicases. Here we develop a novel meth-
odology to study interactions between components of the viral replicase to define essential
cis- and trans-activities for all five hepatitis C virus (HCV) replication gene products. Our
studies show that representative defects in each HCV replication protein can be comple-
mented in trans. However, specific features of NS3 and NS5B were required in cis, indicat-
ing that these proteins specifically function to replicate the genome that encodes them.
These data define important activities of the HCV replication proteins and provide new
insight into how these proteins function together as an enzyme complex.
Introduction
The low-fidelity of RNA virus replication gives rise to swarms of mutant variants [1], which
can genetically interact with one another. Mutant viruses may complement or inhibit one an-
other in trans, with important consequences on virus evolution, pathogenesis, and the emer-
gence of drug-resistance [2–5]. For instance, subgenomic (i.e. less than genome length)
defective-interfering (DI) viruses are dependent on, and compete with, helper viruses with in-
tact genomes [6]. Because of this competition, many positive-strand RNA viruses have evolved
genome quality control mechanisms that require specific viral genes in cis [7–14]. In some
cases, essential cis-acting RNA sequences or secondary structures are embedded within the
viral coding region [15–19]. In other cases, RNA replication requires ribosomal translation
through a specific gene region, although the gene product is not necessarily required in cis
[7,11,20]. Finally, some cis-acting viral proteins recruit the RNA from which they were translat-
ed into RNA replication complexes [9–11,21].
One group of viruses exhibiting marked cis-preferences is the Flaviviridae, a large family of
enveloped, positive-strand RNA viruses that includes several globally important human and ani-
mal pathogens [22]. Members of this family are genetically diverse but share similarities in ge-
nome organization, mechanisms of gene expression, and replication strategies. As a model of
RNA replication, the best-characterized member of this family is hepatitis C virus (HCV), a
human pathogen that causes chronic liver disease, cirrhosis, and liver cancer, and is a major tar-
get of antiviral design [23]. The 9.6-kb HCV genome lacks a 5' cap and 3' polyadenylated tail but
has highly structured 5' and 3' non-coding regions, as well as an internal RNA cis-replication ele-
ment (CRE) within the coding region (Fig 1A). These RNA structures are important cis-acting
sequences that direct translation and replication of the viral genome, including a 5' internal ribo-
some entry site (IRES) to initiate cap-independent translation.
As for all positive-strand RNA viruses, the HCV genome is translated directly, producing a
polyprotein that is cleaved by cellular and viral proteinases into structural proteins—core, E1,
and E2—and nonstructural (NS) proteins—p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B
(Fig 1A and 1B). After multiple rounds of translation, a subset of NS proteins then recruits the
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Fig 1. HCV NS5B can be complemented in trans. (A) Overview of the HCV genome, SGR-Gluc, and the recoded NS3–5B region; CRE, cis-responsive
element; E•I, encephalomyocarditis virus IRES. (B) Model of HCV genome translation, polyprotein processing, and recruitment of the genome out of
translation and into a proto-replication complex. (C) Model of an active, membrane-bound HCV replication complex; red line, negative-strand RNA (D) HCV
replication-dependent expression of Gluc activity. Media were collected at the indicated times post-transfection and assayed as described in Materials and
Methods. Values represent mean ± SD from transfections done in triplicate and normalized to untransfected controls; ***, p< 0.001 by Student's t-test. This
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genome out of translation and into a membrane-bound replication complex (replicase) that
contains multiple copies of NS3–5B (Fig 1B and 1C). The core–NS2 genes are involved in virus
particle assembly but are dispensable for RNA replication [24]; in contrast, NS3–5B are all re-
quired for RNA replication and is the minimal set of HCV genes necessary to produce a self-
replicating subgenomic RNA replicon (SGR) [25]. RNA replication is thought to occur via de
novo (i.e., unprimed) initiation at or near the 3' end of the template genome, production of a
complementary negative strand, and iterative use of the negative strand as a secondary tem-
plate to make many new positive-strand genomes [26,27].
Much is known about the structure and function of individual NS3–5B proteins, although
the molecular architecture of the replicase is not yet known. NS3 is a bifunctional enzyme, en-
coding an N-terminal serine protease domain and a C-terminal helicase domain. The serine
protease requires interaction with NS4A for optimal activity and is responsible for cleaving the
downstream polyprotein [28]; it also proteolytically inactivates specific cellular substrates in-
cluding MAVS [29,30], TRIF [31], DDB1 [32], and GPx8 [33]. The C-terminal RNA helicase/
NTPase activities of NS3 are essential for RNA replication [34,35], although the specific roles
of these activities are unknown. For instance, this domain can unwind double-stranded RNA
and DNA in vitro [36], but direct evidence is lacking that it binds to or unwinds viral RNA dur-
ing the replication cycle in vivo. The small NS4A protein binds to NS3, acts as a cofactor for
both NS3 activities [28,37], and anchors the NS3-4A heterodimer in the membrane [38]. NS4B
is a polytopic membrane protein that can oligomerize and may serve as a scaffold for replicase
assembly [39,40]. NS5A is an RNA-binding phosphoprotein that contains an N-terminal am-
phipathic membrane anchor, a structured zinc-binding domain that directs NS5A homodimer-
ization in either of two alternate conformations, and a large, natively unfolded C-terminal
domain [41]. The precise role of NS5A during RNA replication is not yet clear, but it is known
to recruit cellular factors essential for replicase assembly and function, including cyclophilin A
[42–46], phosphatidylinositol 4-kinase IIIα [47], and the vesicle trafficking protein VAP-A
[48–50]. NS5B is the viral RNA-dependent RNA polymerase and has a C-terminal membrane
tail anchor [51,52]. The NS3 serine protease, NS5B polymerase, and NS5A proteins are the
major targets of HCV-specific antiviral compounds [23].
Mutations in the HCV core-NS2 genes, including large in-frame deletions, can be comple-
mented in trans [53–56]. However, among the genes required for RNA replication, only NS4B
and NS5A have been shown to be trans-complemented [57–62]. These observations have led
to the suggestion that the other NS genes work only in cis, although the underlying basis of
these cis requirements remains unclear. Here, we describe newly developed quantitative tools
to study the cis- and trans-requirements of HCV RNA replication and identify loss-of-function
experiment was performed>12 times with similar results. (E) SGR-Gluc(5Bm1) does not replicate in Huh-7.5[SGR-Neo] cells. Values represent mean ± SD
from transfections done in triplicate and normalized to untransfected controls; ***, p< 0.001 by Student's t-test. This experiment was repeated four times
with similar results. (F) Model of NS3–5B expression from a recoded mRNA. This mRNA is not replicated because it lacks 5', 3', and internal CREs of the
HCV genome. (G) Western blot of NS3 (antibody 9G2), NS5A (antibody 9E10), and actin (antibody AC-15) in lysates prepared from the indicated cell lines.
(H) SGR-Gluc(5Bm1) replicates in Huh-7.5[VEEV/NS3–5B] cells but not in Huh-7.5[VEEV/GFP] cells. Values represent mean ± SD from transfections done
in triplicate and normalized to untransfected controls; **, p< 0.01; ***, p< 0.001 by Student's t-test of SGR-Gluc(5Bm1) in Huh-7.5[VEEV/NS3–5B] vs.
Huh-7.5[VEEV/GFP] cells. This experiment was performed eight times with similar results. (I) HCV RNA copies were determined by RT-qPCR. Values
represent mean ± SD from transfections performed in triplicate and normalized to untransfected controls. This experiment was repeated three times with
similar results. Dotted line, limit of detection for the qRT-PCR assay; *, p< 0.05; **, p< 0.01 by Students t-test of SGR-Gluc(5Bm1) RNA values in Huh-7.5
[VEEV/NS3–5B] vs. Huh-7.5[VEEV/GFP] cells. (J) Complementation of SGR-Gluc(5Bm1) is sensitive to DCV (dashed lines). For comparison, the untreated
SGR-Gluc(mut5B) samples, which were performed in parallel, are reproduced from panel D. Values represent mean ± SD from transfections performed in
triplicate and normalized to untransfected controls. This experiment was repeated three times with similar results. (K) G418-resistant colony formation by
SGR-Neo or SGR-Neo(5Bm1) was determined in the indicated cell lines by crystal violet staining. (L) Complementation of SGR-Gluc(5Bm1), SGR-Gluc
(5Bm2), and SGR-Gluc(5Bm3) in Huh-7.5[VEEV/NS3–5B] cells. Values represent mean ± SD from transfections done in triplicate and normalized to
untransfected controls. This experiment was performed three times with similar results.
doi:10.1371/journal.ppat.1004817.g001
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mutations in NS3, NS4A, and NS5B that can be complemented in trans. Whereas NS5B RNA
binding and polymerase activities could be supplied in trans, NS5B expression was required in
cis, suggesting that NS5B has a structural role in replicase assembly. A subset of NS3 activities
was required in cis, including the helicase RNA binding and NTPase active site residues, impli-
cating these helicase activities in the recruitment of an RNA template for replication. Comple-
mentation group analysis indicated that NS3-4A and NS4B activities are coordinated, whereas
NS5B activity requires an intact set of upstream NS3-5A genes. We followed up on this latter
observation by showing that NS5B segregates with a daclatasvir-sensitive activity of NS5A.
These results reveal new aspects of HCV replicase structure-function, provide insights into
combination anti-HCV therapy, and establish an experimental platform to study the genetic
and functional interactions of gene products from positive-strand RNA viruses.
Results
NS5B can be supplied in trans
HCV SGRs encoding reporter genes provide a quantitative readout of HCV RNA replication
[63,64]. To monitor HCV replication levels over time, we used SGR-Gluc (Fig 1A), an HCV ge-
notype 2a (strain JFH-1) SGR that autonomously replicates and expresses the Gaussia princeps
luciferase (Gluc) [65]. At early times post-transfection of Huh-7.5 hepatoma cells with
SGR-Gluc RNA transcripts, Gluc expression increased and reached maximal expression by
48 hours (Fig 1D); the decline in Gluc activity at later times corresponded with the onset of cy-
topathic effects caused by JFH-1 replication [55,64,66]. In contrast, SGR-Gluc(5Bm1), a mu-
tant replicon containing inactivating point mutations of the Mg++-coordinating polymerase
active site residues (Table 1), expressed Gluc only at early time points post-transfection
(Fig 1D), consistent with translation of the input RNA followed by RNA turnover [65].
We tested whether the replication defect of SGR-Gluc(5Bm1) could be trans-complemented
in Huh-7.5[SGR-Neo] cells, which stably harbor a functional JFH-1 SGR that confers resis-
tance to G418 [66]. SGR-Gluc efficiently replicated in these cells, whereas SGR-Gluc(5Bm1)
did not (Fig 1E). Thus, SGR-Gluc(5Bm1) was not trans-complemented in Huh-7.5[SGR-Neo]
cells, consistent with prior results indicating that NS5B is not supplied in trans by an active rep-
licon [57,61,83]. We hypothesized that active RNA replication competed with complementa-
tion, such that NS5B expressed by a replicon might be unavailable to function in trans. To test
this idea, we expressed NS3–5B outside the context of a functional HCV replicon by using a
recoded 6015-nt NS3–5B gene region containing 1379 silent mutations (Fig 1A, 1F, and S1
Text). The rationale for recoding HCV NS3–5B was to: 1) ensure efficient expression by using
preferred human codons; 2) minimize RNA secondary structures, including known and poten-
tial cis-acting replication elements within the NS3–5B coding region; and 3) allow for selective
amplification of HCV replicons vs. synthetic NS3–5B genes during downstream analysis (e.g.
RT-PCR). The recoded NS3–5B region was expressed in Huh-7.5 cells by using a noncyto-
pathic SGR derived from Venezuelan equine encephalitis virus (VEEV), a member of the
Alphavirus genus of the Togaviridae family of positive-strand RNA viruses. This expression
vector was chosen because noncytopathic alphavirus vectors: 1) stably and abundantly express
foreign genes [84,85]; 2) accommodate large insertions [86]; and 3) have been used successfully
in trans-complementation studies with members of the Flaviviridae, including HCV [86–89].
After stable transduction of Huh-7.5 cells with the VEEV/NS3–5B vector to produce Huh-7.5
[VEEV/NS3–5B] cells, the HCV NS3–5B polyprotein was expressed at physiologically relevant
levels and properly processed through proteolytic cleavage, as evidenced by the patterns of NS3
and NS5A expression (Fig 1G). NS3–5B expression was stable for many weeks of passage. As a
Replication of HCV in trans
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negative control, the green fluorescent protein (GFP) was expressed as an irrelevant protein via
the VEEV vector (VEEV/GFP).
We next investigated whether SGR-Gluc(5Bm1) could be trans-complemented in Huh-7.5
[VEEV/NS3–5B] cells. Indeed, SGR-Gluc(5Bm1) replicated and expressed Gluc in Huh-7.5
[VEEV/NS3–5B] cells but not in Huh-7.5[VEEV/GFP] cells, although the kinetics of Gluc ex-
pression was slower and less robust than from wild-type SGR-Gluc (Fig 1H). In agreement
with the Gluc expression data, SGR-Gluc(5Bm1) RNA levels were maintained in Huh-7.5
[VEEV/NS3–5B] cells, albeit at reduced levels compared to SGR-Gluc RNA (Fig 1I). In con-
trast, SGR-Gluc(5Bm1) RNA levels fell below the limit of detection in Huh-7.5[VEEV/GFP]
cells (Fig 1I). These data demonstrate that an HCV mutant containing an inactivating muta-
tion of the NS5B polymerase active site can be trans-complemented.
To confirm that SGR-Gluc(5Bm1) replicated in Huh-7.5[VEEV/NS3–5B] cells, transfected
cells were treated with 1 nM daclatasvir (DCV), a potent inhibitor of HCV RNA replication
Table 1. Mutants used in this study.
Mutationsa
Gene Name JFH-1 H77 Rationale References
NS5B 5Bm1 D318N D2738 NS5B polymerase active site, Mg++ coordination [25,34,67]
D319N D2739
5Bm2 R168A R2588 NS5B RNA binding groove [68,69]
K172A K2592
5Bm3 As above Combined 5Bm1 and 5Bm2 This study
5A*5B S1 S2421 Nonsense mutation at NS5B start
5Brc n.a. Recoded NS5B to create -1 ORF This study
5Bfs T40–R592 -1 Frameshift at NS5B codon 40 This study
NS3 3m1 H57A H1083 Serine protease active site [70]
3m2 S139A S1165 Serine protease active site [70,71]
3m3 T269A T1295 Helicase RNA binding [72,73]
3m4 D290A D1316 Helicase NTPase active site [34,72,74]
E291A D1317
3m5 W501A W1527 Helicase stacking [73,75–77]
3m6 ΔF184 F1210 Linker between the NS3 serine protease and helicase domains [78]
ΔS185 T1211
ΔD186 D1212
3m7 P190G P1216 Linker between the NS3 serine protease and helicase domains [78]
P191G P1217
NS4A 4Am1 Y45A Y1702 Essential, conserved Tyr in NS4A C-terminal acidic domain [65,79]
4Am2 A11L A1668 NS4A transmembrane dimerization [80]
NS4B 4Bm1 E226A E1937 Determinant of NS4B homotypic interaction and membrane alteration [40,58]
NS5A 5Am1 S232I S2204 Determinant of NS5A hyperphosphorylation [58,81,82]
DCVR F28S M2000 Daclatasvir resistance [59]
NS3–NS5A 3–5Arc n.a. Recoded NS3 codon 111 to NS5A codon 120 This study
NS3, NS5B 3&5Bm As above Combined 3m6 and 5Bm1 This study
NS4A–NS5A 4A–5Am As above Combined 4Am1, 4Bm1, and 5Am1 This study
NS3–NS5B 3–5Bm As above Combined 3m6, 4Am1, 4Bm1, 5Am1, and 5Bm1 This study
aResidues are numbered by their codon position within each gene of the JFH-1 subgenomic replicon or in the polyprotein of HCV reference strain H77;
n.a., not applicable.
doi:10.1371/journal.ppat.1004817.t001
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complex assembly [90–92]. DCV inhibits JFH-1 replication with an effective concentration
(EC50) of 71 pM and cytostatic concentrations (CC50) of>10 μM [90,93]. Treatment with 1
nM DCV abolished replication of SGR-Gluc(5Bm1) in Huh-7.5[VEEV/NS3–5B] cells (Fig 1J),
confirming that the observed trans-complementation of SGR-Gluc(5Bm1) requires HCV
replicase activity.
We next examined the essential features of NS5B supplied in trans. As expected, comple-
mentation of SGR-Gluc(5Bm1) required an intact polymerase active site in the recoded NS3–
5B polyprotein (S1A Fig). Furthermore, expression of NS5B alone, either by introducing an ini-
tiator Met codon (Met-NS5B) or by fusion with ubiquitin to ensure an authentic NS5B N-
terminal Ser residue (Ubi-NS5B), failed to trans-complement SGR-Gluc(5Bm1) (S1B Fig). Pro-
cessing of Ubi-NS5B into NS5B was confirmed by western blot (S1C Fig), consistent with effi-
cient cleavage of N-terminal Ubi fusions by cellular ubiquitin C-terminal hydrolases [94,95].
These data indicate that expression of NS5B alone is insufficient to trans-complement a defect
in NS5B polymerase activity, suggesting that NS5B may need to be expressed as part of the
NS3–5B polyprotein.
We also examined the trans-complementation of a full-length HCV reporter virus, Jc1/
Gluc2A [96], containing the 5Bm1 mutation. As expected, this mutant was unable to replicate
in Huh-7.5, Huh-7.5[VEEV/GFP], or Huh-7.5[SGR-Neo] cells, but replicated in Huh-7.5
[VEEV/NS3–5B] cells (S1D Fig). However, the dynamic range of trans-complementation (i.e.,
the ratio between the highest and lowest Gluc signals) was lower for Jc1/Gluc2(5Bm1) than for
SGR-Gluc(5Bm1), consistent with the higher replication efficiency of SGRs vs. full-length
HCV genomes [55,97]. As a result, only low titers (2.3 x 103 TCID50 units/ml) of infectious
virus (as assayed on Huh-7.5[VEEV/NS3–5B] cells) were obtained from the full-length 5Bm1
mutant. Since our focus was to characterize the cis- and trans- activities of NS genes during
RNA replication, SGRs were used in further studies because of their superior dynamic range in
replication-dependent Gluc expression.
To determine the long-term stability of NS5B trans-complementation, we tested the ability
of SGR-Neo(5Bm1) to replicate and transduce Neo-expression in Huh-7.5[VEEV/NS3–5B]
cells. As shown in Fig 1K, SGR-Neo(5Bm1) formed G418-resistant colonies in Huh-7.5
[VEEV/NS3–5B] cells with an efficiency similar to the wild-type SGR-Neo replicon. Following
selection with G418, SGR-Neo(5Bm1) replicon-bearing Huh-7.5[VEEV/NS3–5B] cells could
be maintained under selection indefinitely. The 5Bm1 mutation (“GNN”) was maintained sta-
bly in G418-selected SGR-Neo(5Bm1) replicon-bearing cells, as seen by direct sequencing of
the resulting reverse-transcribed and PCR-amplified amplicon (S1E Fig) and by cloning the
PCR product and sequencing twenty independent clones. Although reversion is possible, it was
not observed in these experiments. Thus, stable replication of the SGR-Neo(5Bm1) replicon
was not due to reversion or recombination with the recoded NS5B gene.
We also tested the trans-complementation of an NS5Bmutant containing inactivating muta-
tions in the polymerase RNA binding groove, SGR-Gluc(5Bm2), as well as a third mutant,
SGR-Gluc(5Bm3), which contained both RNA binding and polymerase active site mutations
(Table 1). These mutants were trans-complemented with efficiencies similar to SGR-Gluc(5Bm1)
(Fig 1L). In contrast to prior results [57,61,83], these data establish that defects in NS5B can be
complemented in trans by expressing NS3–5B outside the context of an actively replicating SGR.
NS5B protein expression is required in cis for RNA replication
We next examined whether the efficiency of NS5B complementation could be improved by
preventing expression of the defective NS5B protein. However, the NS5B gene cannot simply
be deleted because it contains an RNA structural element, the CRE, required for RNA
Replication of HCV in trans
PLOS Pathogens | DOI:10.1371/journal.ppat.1004817 April 13, 2015 7 / 30
replication. We therefore inserted a stop codon just downstream of NS5A to create SGR-Gluc
(5A5B) (Table 1 and Fig 2A). This mutant was unable to replicate, but surprisingly, was not
complemented in trans (Fig 2B). We considered three explanations for these observations.
First, the premature stop codon destabilized the SGR-Gluc(5A5B) RNA. However, SGR-Gluc
(5Bm1) and SGR-Gluc(5A5B) expressed similar levels of residual Gluc (Fig 2B); given that na-
scent Gluc was collected at each time point (Materials and Methods), these data suggest that
non-replicating SGR-Gluc(5Bm1) and SGR-Gluc(5A5B) RNAs were turned over at similar
rates. Second, RNA replication required ribosomal transit through the NS5B coding region, as
has been observed for the 2A–3D coding region of poliovirus [11]. Third, the NS5B protein
was required in cis. To distinguish between these possibilities, we designed a strategy to permit
ribosomal translation through the NS5B coding region, without NS5B expression, by using an
alternate reading frame. First, we designed the SGR-Gluc(5Brc) mutant containing 22 silent
mutations in the NS5B coding region that: 1) removed stop codons from the -1 reading frame;
2) maintained the CRE structure; and 3) maintained a stop at codon 592 (Fig 2A and S2 Text).
Thus, this mutant expresses a wild-type NS3–5B polyprotein but uses altered NS5B codon
usage to create an untranslated -1 open reading frame. SGR-Gluc(5Brc) autonomously and ef-
ficiently replicated, although with slightly delayed kinetics compared to SGR-Gluc (Fig 2C), in-
dicating that these silent mutations in NS5B had only a minor effect on RNA replication.
We then introduced a -1 frame-shift at codon 39 of the SGR-Gluc(5Brc) NS5B gene, to cre-
ate SGR-Gluc(5Bfs), a mutant predicted to express a 65.3-kDa, 591 amino acid protein, 5Bfs, of
Fig 2. NS5B protein is required in cis. (A) Constructs used to examine the cis-requirement for NS5B expression, as detailed in the text; asterisk, stop
codon; dotted lines, untranslated coding regions; fs, -1 frame-shift. For more information, also see Table 1 and S2 Text. (B) SGR-Gluc(5A*5B) does not
replicate and is not complemented in trans. Values represent mean ± SD from transfections done in triplicate and normalized to untransfected controls. This
experiment was performed three times with similar results. (C) SGR-Gluc(5Brc) replicates efficiently. Values represent mean ± SD from transfections done in
triplicate and normalized to untransfected controls; n.s., p 0.05; *, p< 0.05; **, p< 0.01 by Students t-test. This experiment was performed three times
with similar results. (D) SGR-Gluc(5Bfs) does not replicate and is not replicated in trans. Values represent mean ± SD from transfections done in triplicate and
normalized to untransfected controls. This experiment was performed three times with similar results. (E) The SGR-Gluc(5Brc) and SGR-Gluc(5Bfs)
polyproteins are expressed and properly cleaved, as determined by western blot with 4D11 anti-NS3 and 9E10 anti-NS5Amonoclonal antibodies. Because
these mutants do not replicate, expression was driven by the vaccinia-T7 RNA polymerase system.
doi:10.1371/journal.ppat.1004817.g002
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unknown structure instead of the 66.7-kDa, 591 amino acid NS5B protein (S2 Text). The
SGR-Gluc(5Bfs) mutant did not replicate, nor was it trans-complemented (Fig 2D). One possi-
ble explanation was that the 5Bfs protein non-specifically interfered with HCV replication.
However defects in SGR-Gluc replication were not observed when a 5Bfs transgene was ex-
pressed in trans, arguing that the 5Bfs-encoded protein did not have a dominant negative effect
on replication. We also considered the possibility that the frame-shift could have caused defects
in processing of the NS3–5Bfs polyprotein. Because 5Bfs includes the N-terminal 39 amino
acids of NS5B, it should allow proper processing of the NS5A/5B junction. Consistent with
this, SGR-Gluc(5Bfs) expressed normal levels of NS3 and NS5A but not NS5B (Fig 2E), indicat-
ing that proper cleavage of the polyprotein occurred and that normal levels of NS3 and NS5A
were expressed. Together, these data show that the recoded NS3–5B transgene was unable to
trans-complement SGR-Gluc(NS5Bfs), a mutant that: 1) lacks a premature stop codon; 2) al-
lows ribosomes to translate through the NS5B coding region; but 3) does not express NS5B.
Thus, two mutants lacking NS5B expression, SGR-Gluc(5A5B) and SGR-Gluc(5Bfs), were not
complemented in trans. The simplest interpretation of these data is that RNA replication re-
quires NS5B protein translation in cis. Since defects in NS5B RNA binding and polymerase ac-
tivities can be trans-complemented (Fig 1), this cis-requirement is therefore independent of the
known enzymatic activities of NS5B.
NS3 serine protease and RNA helicase activities are required in cis
Given the success in trans-complementing NS5B, we examined whether defects in other HCV
NS genes could be trans-complemented in Huh-7.5[VEEV/NS3–5B] cells. We initially tested
mutants containing lethal, inactivating mutations of the NS3 serine protease active site residues
(Table 1), SGR-Gluc(3m1) and SGR-Gluc(3m2). Neither of these protease mutants replicated,
nor were they complemented in trans (Fig 3A). We also examined NS3 RNA helicase domain
mutants SGR-Gluc(3m3) and SGR-Gluc(3m4), which contained loss-of-function mutations
abrogating RNA binding and NTPase activity, respectively (Table 1). Neither of the helicase
domain mutants replicated, nor were they complemented in trans (Fig 3B). In comparison, a
third helicase domain mutant, SGR-Gluc(3m5) was trans-complemented at levels similar to
the 5Bm1 mutant (Table 1 and Fig 3C). As detailed in the Discussion, SGR-Gluc(3m5) is a
loss-of-function mutant that lacks RNA unwinding activity but retains NS3 helicase RNA
binding and NTPase activities [75–77].
Although the data above suggested that HCV replication required the enzymatic activities
of NS3 in cis, two alternative interpretations are that these specific NS3 mutations: 1) destabi-
lized the inactive NS3 proteins, which could be required in cis; or 2) disrupted underlying RNA
structures within the NS3 gene that are required in cis. Western blot analysis indicated that the
3m3 and 3m5 mutations caused slight (2-fold) increases in NS3 accumulation, and that the
3m4 mutation had no effect on NS3 accumulation (Fig 3D). As expected, the 3m1 mutation ab-
rogated serine protease cleavage activity and caused accumulation of an unprocessed NS3–5B
polyprotein (Fig 3D). These data show that the helicase mutations did not inhibit NS3 protein
accumulation. To examine whether the NS3 mutations disrupted a putative underlying RNA
structure required for replication, we replaced a large portion of a full-length HCV genome
with the corresponding NS3-5A region from the recoded NS3–5B cassette, creating the
Jc1-Gluc(3-5Arc) mutant (Fig 3E and Table 1). This mutant contained 524 silent mutations,
including the NS3 RNA binding and NTPase active site codons T269, D290, and E291 that had
been mutated in 3m3 and 3m4 (S3 Text). As expected, the recoded NS3 gene also exhibited
pronounced differences in predicted RNA secondary structure (S2 Fig). The Jc1-Gluc(3-5Arc)
mutant replicated efficiently with only a slight delay in kinetics (Fig 3F); it is therefore unlikely
Replication of HCV in trans
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Fig 3. Complementation of NS3 serine protease and RNA helicase active site mutants. (A) Serine protease active site mutants SGR-Gluc(3m1) and
SGR-Gluc(3m2) do not replicate and are not complemented in trans. Values represent mean ± SD from transfections done in triplicate and normalized to
untransfected controls. This experiment was performed two times with similar results. (B) Helicase RNA binding and NTPase active site mutants SGR-Gluc
(3m3) and SGR-Gluc(3m4) do not replicate and are not complemented in trans. Values represent mean ± SD from transfections done in triplicate and
normalized to untransfected controls. For comparison, the SGR-Gluc samples, which were performed in parallel, are reproduced from panel A. This
experiment was performed two times with similar results. (C) RNA helicase base stacking mutant SGR-Gluc(3m5) does not replicate but is complemented in
transwith an efficiency similar to SGR-Gluc(5m1). For comparison, the SGR-Gluc samples, which were performed in parallel, are reproduced from panel A.
Values represent mean ± SD from transfections done in triplicate and normalized to untransfected controls; *, p< 0.05; **, p<0.01 by Student’s t-test,
comparing matched time points from SGR-Gluc(3m5) in Huh-7.5[VEEV/NS3–5B] vs. Huh-7.5[VEEV/GFP] cells. This experiment was performed two times
with similar results. (D) Western blot to confirm that the serine protease active site mutant SGR-Gluc(3m1) does not undergo polyprotein cleavage and that
the RNA helicase mutants SGR-Gluc(3m2), SGR-Gluc(3m3), SGR-Gluc(3m4), and SGR-Gluc(3m5) do not exhibit defects in NS3 accumulation. NS3 was
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that the 3m3 and 3m4 mutations disrupted an important RNA element in the NS3 gene region.
Given that the inactivating NS3 helicase mutations did not inhibit NS3 protein accumulation
nor disrupt important RNA secondary structures, we conclude that HCV RNA replication re-
quires the RNA binding and NTPase activities of the NS3 RNA helicase domain in cis. While
the serine protease activity is required in cis because it is needed for polyprotein processing
(Fig 3G), the RNA binding and NTPase activities of the helicase domain are likely needed for a
post-translational step in replication, such as RNA template recruitment (Fig 3H).
trans-complementation of NS3–5B genes
We also examined the trans-complementation of additional NS3-4A mutants. The SGR-Gluc
(3m6) mutant, which contains a loss-of-function, three-codon deletion in the NS3 linker re-
gion [78], replicated to high levels in Huh-7.5[VEEV/NS3–5B] cells (Fig 4A), indicating that it
was trans-complemented. This mutant was also complemented in Huh-7.5[SGR-Neo] cells
(Fig 4B), indicating that, unlike NS5B, NS3 can be complemented by an actively replicating
replicon. Similarly, the SGR-Gluc(4Am1) mutant, which contains a lethal codon substitution
in the NS4A acidic domain [65,79], replicated in both Huh-7.5[VEEV/NS3–5B] cells (Fig 4C)
and Huh-7.5[SGR-Neo] cells (Fig 4D). Efficient trans-complementation was also observed for
mutants SGR-Gluc(3m7) and SGR(4Am2), which contained lethal mutations in the NS3 linker
and NS4A transmembrane domains, respectively (Table 1 and S2C Fig). Together, these data
confirm that NS3-4A can be complemented in trans, either by expressing a recoded NS3–5B
region or by an actively replicating SGR.
Prior work has shown that NS4B and NS5A can be supplied in trans [57–61]. Consistent
with these results, SGR-Gluc(4Bm1) and SGR-Gluc(5Am1) (Table 1) had severe replication de-
fects in Huh-7.5[VEEV/GFP] cells but were trans-complemented in Huh-7.5[VEEV/NS3–5B]
cells (S3A and S3B Fig). Both mutants also were complemented in Huh-7.5[SGR-Neo] cells
(S3C and S3D Fig), confirming that defects in NS4B and NS5A can be complemented in trans
by expressing the wild-type gene either from an active replicon or from a synthetic mRNA en-
coding NS3–5B.
We then examined whether multiple defects could be complemented simultaneously by
combining two (3m6 and 5Bm1), three (4Am1, 4Bm1, and 5Am1), or five inactivating muta-
tions (3m6, 4Am1, 4Bm1, 5Am1, and 5Bm1) within the SGR-Gluc replicon (Table 1). All of
the combined mutants replicated in Huh-7.5[VEEV/NS3–5B] cells but not in Huh-7.5[VEEV/
GFP] cells (Fig 5A–5C). The efficiency of complementation inversely correlated with the num-
ber of mutations; nevertheless, replication levels were statistically significant and sensitive to
DCV treatment, confirming that these signals were due to active HCV replication. None of the
combined mutants replicated in Huh-7.5[SGR-Neo] cells (S4A–S4C Fig). To examine the
long-term trans-complementation of a mutant containing multiple defects, we used G418 se-
lection of a mutant SGR-Neo replicon. As shown in Fig 5D, SGR-Neo(3–5Bm) stably replicated
and formed G418-resistant colonies in Huh-7.5[VEEV/NS3–5B] cells but not in Huh-7.5
[VEEV/GFP] cells. RT-PCR and sequence analysis of twelve independent cDNA clones con-
firmed that the 3m6, 4Am1, 4Bm1, 5Am1, and 5Bm1 mutations were all retained in the
detected by using anti-NS3 monoclonal antibody 4E11; values represent relative NS3 levels compared to SGR-Gluc. Because these mutants do not
replicate, expression was driven by the vaccinia-T7 RNA polymerase system. (E) Design of the Jc1-Gluc(3–5Arc) mutant. (F) Jc1-Gluc(3–5Arc) replicates
efficiently. Values represent mean ± SD from transfections done in triplicate and normalized to untransfected controls; n.s., p>0.05, *, p 0.05 by Student’s
t-test. This experiment was performed two times with similar results (G) Model showing that SGR-Gluc(3m1) and SGR-Gluc(3m2) do not undergo proteolytic
processing, produce misfolded, inactive polyproteins, and are not complemented in trans; grey signifies the nonfunctional serine protease domains; blue
signifies the recoded NS3-5B polyprotein. (H) Model showing that SGR-Gluc(3m3) and SGR-Gluc(3m4) are not trans-complemented and may have a defect
in RNA recruitment (compare to Fig 1B); grey signifies the nonfunctional helicase domains; blue signifies the recoded NS3-5B polyprotein.
doi:10.1371/journal.ppat.1004817.g003
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G418-selected cell populations. These data demonstrate that HCV replicons with combined de-
fects in all five NS genes required for RNA replication (NS3, NS4A, NS4B, NS5A, and NS5B)
can be complemented in trans (Fig 5E).
NS3–5B complementation group analysis
The ability to complement defects in each NS3–5B gene enabled us to examine functional in-
teractions between NS genes through complementation group analysis (Fig 6). To do so, we
first created Huh-7.5[VEEV/NS3–5B] cell lines containing the 3m6, 4Am1, 4Bm1, 5Am1, and
5Bm1 mutations within the recoded NS3–5B transgene. Wild-type SGR-Gluc replicated simi-
larly in all cell lines (Fig 6A), indicating that the mutant NS3–5B transgenes did not have domi-
nant negative effects on HCV replication. A panel of SGR-Gluc NS3–5B mutants was then
tested for complementation in these cell lines. As expected, each SGR-Gluc mutant failed to
replicate in cells expressing the NS3–5B transgene containing a defect in the same gene
(Fig 6), thus defining distinct complementation groups. Nonetheless, the efficiency of trans-
complementation varied among mutant genes, suggesting that functional interactions exist be-
tween the corresponding gene products. Notably, the 3m6 mutant replicated less efficiently in
Huh-7.5[VEEV/NS3–5B(4Bm1)] cells than in Huh-7.5[VEEV/NS3–5B] cells (Fig 6B); the
4Am1 mutant replicated less efficiently in Huh-7.5[VEEV/NS3–5B(3m6)] and Huh-7.5
[VEEV/NS3–5B(4Bm1)] cells than in Huh-7.5[VEEV/NS3–5B] cells (Fig 6C); and the 4Bm1
mutant replicated less efficiently in Huh-7.5[VEEV/NS3–5B(3m6)] cells than in Huh-7.5
[VEEV/NS3–5B] cells (Fig 6D). These data indicate that the NS3-4A and NS4B activities were
enhanced by co-expression of these genes from the same polyprotein (Fig 6G). However, the
most notable effect was that SGR-Gluc(5Bm1) failed to replicate in Huh-7.5[VEEV/NS3–5B
Fig 4. HCV NS3-4A can be complemented in trans. (A) Efficient replication of SGR-Gluc(3m6) in Huh-7.5[VEEV/NS3–5B] cells but not in Huh-7.5[VEEV/
GFP] cells. The replication of SGR-Gluc in Huh-7.5[VEEV/GFP] cells is shown for comparison. (B) Replication of SGR-Gluc(3m6) in Huh-7.5[SGR-Neo] cells
but not in Huh-7.5 cells. The replication of SGR-Gluc in Huh-7.5 cells is shown for comparison. (C) Replication of SGR-Gluc(mut4A) in Huh-7.5[VEEV/NS3–
5B] cells but not in Huh-7.5[VEEV/GFP] cells. This experiment was performed in parallel with the experiment shown in (A); the replication of SGR-Gluc in
Huh-7.5 cells is reproduced for comparison. (D) Replication of SGR-Gluc(4Am1) in Huh-7.5[SGR-Neo] cells but not in Huh-7.5 cells. This experiment was
performed in parallel with the experiment shown in (B); the replication of SGR-Gluc in Huh-7.5 cells is reproduced for comparison. All values represent
mean ± SD from transfections done in triplicate and normalized to untransfected controls; *, p< 0.05; **, p< 0.01; ***, p<0.001 by Students t-test,
comparing matched Gluc activity of SGR-Gluc(3m6) or SGR-Gluc(4Am1) in complementing vs. non-complementing cell lines at each time point. Each
experiment was performed twice with similar results.
doi:10.1371/journal.ppat.1004817.g004
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(3m6)], Huh-7.5[VEEV/NS3–5B(4Am1)], and Huh-7.5[VEEV/NS3–5B(4Bm1)] cells and was
poorly complemented in Huh-7.5[VEEV/NS3–5B(5Am1)] cells (Fig 6F). These data indicate
that trans-complementing activity of NS5B depends on upstream NS3-5A activities within the
same polyprotein (Fig 6H), consistent with our observation that the 5Bm1 mutant was not
trans-complemented by expression of NS5B alone (S1A Fig). In contrast, the efficient replica-
tion of SGR-Gluc(3m6), SGR-Gluc(4Am1), SGR-Gluc(4Bm1), and SGR-Gluc(5Am1) on Huh-
7.5[VEEV/NS3–5B(5Bm1)] cells (last column of Fig 6B–6F) indicates that the activity of NS5B
in cis does not depend on upstream NS3–5A activities (Fig 6I).
NS5B activity segregates with a DCV-sensitive NS5A activity
Trans-complementation can impact the emergence of drug-resistance [2–4]. Given that trans-
complementation of NS5B is linked to the function of upstream NS3-5A genes, we hypothe-
sized that NS5B activity would segregate with sensitivity to an HCV-specific direct acting anti-
viral compound targeting an upstream gene product. To explore this hypothesis, we examined
the complementation of the lethal 5Bm1 mutation in combination with DCVR, a point
Fig 5. Complementation of NS3–5B in trans. (A) Complementation of NS3 and NS5B in trans. Replication of SGR-Gluc(3&5Bm) and SGR-Gluc was
tested in the indicated cell lines. Cultures were treated with DCV (dashed line). For comparison, the replication of SGR-Gluc in Huh-7.5[VEEV/NS3–5B] cells
(performed in parallel) is shown. (B) Complementation of NS4A, NS4B, and NS5A in trans. Replication of SGR-Gluc(4A–5Am) was tested in the indicated
cell lines and plotted as in (A). This experiment was performed in parallel with the experiment shown in (A); the replication of SGR-Gluc in Huh-7.5[VEEV/
NS3–5B] cells is reproduced for comparison. (C) Complementation of NS3-NS5B in trans. Replication of SGR-Gluc(3–5Bm) was tested in the indicated cell
lines and plotted as in (A). All values represent mean ± SD from transfections done in triplicate and normalized to untransfected controls; *, p< 0.05;
**, p< 0.01; by Student’s t-test, comparing matched time points of each mutant in Huh-7.5[VEEV/NS3–5B] vs. Huh-7.5[VEEV/GFP] cells. Each experiment
was performed twice with similar results. (D) Stable replication of SGR-Neo(mut3,4A,4B,5A,5B) in Huh-7.5[VEEV/NS3–5B] cells. G418-resistant colonies
were stained with crystal violet. (E) Model showing that the replication of SGR-Neo(3–5Bm) (grey) is trans-complemented by recoded NS3–5B (blue).
doi:10.1371/journal.ppat.1004817.g005
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Fig 6. Complementation group analysis. All samples were collected in parallel; therefore, for each mutant, replication in Huh-7.5[VEEV/NS3–5B] and Huh-
7.5[VEEV/GFP] cells (green and red lines, respectively) are reproduced for comparison. Values represent mean ± SD from transfections done in triplicate
and normalized to untransfected controls; *, p< 0.05; **, p< 0.01; **, p< 0.001 by Student’s t-test, comparing matched time points of each mutant in Huh-
7.5[VEEV/NS3–5B(mutant)] cells vs. Huh-7.5[VEEV/NS3–5B] cells. Each experiment was performed twice with similar results. (A) SGR-Gluc replication in
Huh-7.5[VEEV/NS3–5B] (green), Huh-7.5[VEEV/GFP] (red), or each Huh-7.5[VEEV/NS3–5B] mutant (blue). (B) Replication of the SGR-Gluc(3m6) mutant
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mutation in NS5A (Table 1) that shifts the EC50 of DCV by>7,500-fold and renders HCV re-
sistant to DCV [59]. As expected, replication of the SGR-Gluc(DCVR) mutant was resistant to
DCV (Fig 7A). When the DCVR mutation was introduced into VEEV/NS3–5B or VEEV/NS3–
5B(5Bm1), SGR-Gluc replication was resistant to DCV but showed a kinetic lag (Fig 7B and
7E), again confirming that NS5A can be supplied in trans. Surprisingly, trans-complementa-
tion of the SGR-Gluc(5Bm1,DCVR) double mutant was sensitive to DCV (Fig 7C and 7F).
However, trans-complementation of SGR-Gluc(5Bm1) was resistant to DCV when the DCVR
in each cell line. (C) Replication of the SGR-Gluc(4Am1) mutant in each cell line. (D) Replication of the SGR-Gluc(4Bm1) mutant in each cell line. (E)
Replication of the SGR-Gluc(5Am1) mutant in each cell line. (F) Replication of the SGR-Gluc(5Bm1) mutant in each cell line. (G) Model showing that
SGR-Gluc(3m6) replication is trans-complemented inefficiently in Huh-7.5[VEEV/NS3–5B(4Bm1)] cells. (H) Model showing that SGR-Gluc(5Bm1) replication
is not complemented in Huh-7.5[VEEV/NS3–5B(4Bm1)] cells. (I) Model showing that SGR-Gluc(4Bm1) replication is trans-complemented efficiently in Huh-
7.5[VEEV/NS3–5B(5Bm1)] cells.
doi:10.1371/journal.ppat.1004817.g006
Fig 7. NS5B trans-complementation activity segregates with a DCV-sensitive NS5A activity. (A) DCVR confers resistance to DCV. Replication of
SGR-Gluc and SGR-Gluc(DCVR) was tested in Huh-7.5[VEEV/NS3–5B] cells. (B) DCVR confers resistance to DCV in trans. Replication of SGR-Gluc was
tested in Huh-7.5[VEEV/NS3–5B(DCVR)] and Huh-7.5[VEEV/NS3–5B(5Bm1,DCVR)] cells. (C) trans-complementation of SGR-Gluc(5Bm1,DCVR) is
sensitive to DCV. Replication of SGR-Gluc(5Bm1) and SGR-Gluc(5Bm1,DCVR) was tested in Huh-7.5[VEEV/NS3–5B] cells. Values represent mean ± SD
from transfections performed in triplicate, and normalized to untransfected controls. This experiment was performed twice with similar results. (D) Replication
of SGR-Gluc was tested in Huh-7.5[VEEV/NS3–5B(DCVR)] and Huh-7.5[VEEV/NS3–5B(5Bm1,DCVR)] cells. All values represent mean ± SD from
independent transfections performed in triplicate and normalized to untransfected controls; *, p<0.05; **, p<0.01 by Student’s t-test comparing matched
time points to samples treated with 1 nM DCV (dashed lines). All experiments were performed twice with similar results. (E) Model showing that SGR-Gluc
replication is DCV-insensitive in Huh-7.5[VEEV/NS3–5B(5Bm1,DCVR)] cells due to trans-complementation of NS5A. (F). Model showing that SGR-Gluc
(5Bm1,DCVR) replication via NS5B trans-complementation remains DCV-sensitive in Huh-7.5[VEEV/NS3–5B] cells. (G) Model showing that SGR-Gluc
(5Bm1) replication is trans-complemented and DCV-insensitive in Huh-7.5[VEEV/NS3–5B(DCVR)] cells.
doi:10.1371/journal.ppat.1004817.g007
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mutation was introduced into VEEV/NS3–5B (Fig 7D and 7G). These data show that NS5A,
and in particular, the DCV-sensitive function of NS5A, can function in trans, independent of
NS5B. However, the trans-complementation activity of NS5B segregated with an NS5A activity
that was sensitive to DCV, again confirming that NS5B is linked functionally to upstream NS3-
5A activities within the same polyprotein.
Discussion
In this study we define essential cis- and trans-replication activities for all five HCV replicase
genes. Previous studies showed that defects in HCV NS4B and NS5A were complemented in
trans, whereas defects in NS3 and NS5B were not, leading to the suggestion that NS3-4A and
NS5B can only function in cis [57–61]. In contrast, we found that specific genetic defects in
HCV NS3, NS4A, NS4B, NS5A, and NS5B can be complemented in trans, yet other NS3 and
NS5B activities are required in cis.
How do viral genes and their gene products work in cis? In the simplest case, a viral coding
region can contain an important RNA sequence or secondary structure, such as the CREs pres-
ent within the poliovirus 2C gene [15,16] or HCV NS5B gene [17–19]. In other cases, the pro-
cess of RNA translation is required although the protein product may be irrelevant, such as the
ORF encoded by DIs of mouse hepatitis virus [7,20]. As previously noted by Novak and Kirke-
gaard [11], such cis-translational requirements can be explained by ribosome-induced structur-
al changes within the RNA template (Fig 8A), or by recruitment of ribosome-associated factors
to the template. Finally, cis-acting viral proteins can recruit the RNA from which they were
translated into a replication complex. For instance, the nascent N-terminal polypeptide of
Fig 8. Models of viral cis-activities and HCV replicase structure and function. (A) Ribosome-induced change in RNA structure. (B) Nascent cis-acting
polypeptide (orange) recruiting the viral RNA-ribosome complex to a site of replication via an interaction partner (yellow). (C) A cis-acting protein (orange)
recruiting the viral RNA to site of replication. (D) NS5B trans-complementation via protein transfer. (E) NS5B trans-complementation via RNA transfer. (F)
NS5B trans-complementation requires NS3–5B expression. (G) Translation of NS5B is required in cis. (H) Potential NS3-NS4A interactions of the 3m6 and
4Am1mutants. NS3-4A can form homodimers where each monomer contributes either NS3 or NS4A (left); alternatively, NS3-NS4A may dissociate and
reassociate to form separate active and inactive monomers (right).
doi:10.1371/journal.ppat.1004817.g008
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bovine coronavirus nsp1 targets its RNA template to sites of replication [9]; a similar mecha-
nism has been observed for brome mosaic virus 2a protein [98]. In these cases, the nascent
polypeptides are linked physically to the RNA through the actively translating ribosome (Fig
8B). Alternatively, cis-acting proteins that have completed synthesis may bind preferentially to
their RNA template (Fig 8C) due to spatial limitations, such as physical barriers to protein dif-
fusion, or temporal restrictions, such rapid protein turnover [11]. Similar mechanisms have
been put forth to explain cis-acting proteins encoded by DNA viruses and other mobile genetic
elements [99–104].
The cis and trans activities of NS5B
When expressed by an HCV replicon, NS5B exhibited a marked cis-preference and was unable
to trans-complement replicons with defects in NS5B. These data agree with prior studies,
which used replicons as the source of NS5B [57,61,83]. However, NS5B could function in trans
when it was expressed as part of a synthetic NS3–5B polyprotein. We envision two non-
exclusive mechanisms by which this could occur within a replication complex: 1) by intermin-
gling of NS proteins and exchange of NS5B (Fig 8D); and/or 2) by transfer of template RNA
(Fig 8E). In favor of the RNA transfer model, SGR-Gluc(5Bm1) was not complemented when
NS5B was expressed alone (Fig 8F), nor was it complemented by NS3–5B polyproteins con-
taining defects in NS3, NS4A, NS4B, or NS5A (Fig 6H). Thus, trans-complementation of NS5B
may utilize RNA transfer; at the molecular level, this could reflect a propensity of NS5B to re-
main associated with the NS proteins with which it was translated. Nevertheless, protein ex-
change likely occurs during complementation of other viral proteins. For instance NS5A
activity segregates promiscuously, independent of other NS protein activities.
While replicons expressing enzymatically inactive NS5B were complemented in trans, repli-
cons lacking NS5B expression were not. We excluded nonspecific effects caused by a premature
stop codon and a potential requirement for ribosomal transit through the NS5B coding region.
These data indicate that NS5B has a cis-acting role in replicase assembly that is independent of
its RNA binding and polymerase activities. Recent work has shown that the RNA polymerase
of poliovirus plays an important, non-enzymatic role in RNA replication by assembling two-
dimensional, membrane-bound oligomeric lattices that enhance RNA binding and synthesis
through cooperativity [105–107]. Intriguingly, HCV NS5B also forms oligomers that show
cooperativity in RNA synthesis rates [108]. Together, these data lend support to a conserved,
structural role for viral polymerases during positive-strand RNA virus replicase assembly.
Complementation of HCV NS5B in trans only occurred when NS5B was expressed by an in-
tact NS3-5B polyprotein. Analogously, trans-complementation of the NS5 polymerase from
the related West Nile virus (subtype Kunjin; genus Flavivirus) also requires co-expression of
upstream NS proteins [86], suggesting this may be common within the Flaviviridae. We found
that HCV NS5B was functionally linked to NS5A, and more specifically, to the DCV-sensitive
function of NS5A translated from the same polyprotein. Fridell and colleagues used SGR trans-
complementation to define three NS5A complementation groups and showed that the DCV-
sensitive function of NS5A works preferentially in cis [59,60]. In contrast, we found that the
DCVR allele of NS5A can function in trans when it was expressed from a synthetic NS3–5B
mRNA. Thus, the cis-preferences of NS5A and NS5B can be overcome by expressing NS3–5B
outside the context of a functional replicon.
Complementation of NS5A also requires expression of an intact NS3-5A polyprotein
[57,62] or an active replicon [57–61]. Similar results were observed for NS5A complementation
with bovine viral diarrhea virus-1 (BVDV-1), a related member of the Flaviviridae [13]. These
observations may be related to the influence of upstream proteins on the phosphorylation
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status and interactome of NS5A [109–112]. Thus, there appears to be multiple layers of cis-
linkage, whereby NS5B activity is dependent on upstream NS5A activity (this study), which in
turn is linked to the activities of NS3-4A and NS4B. This network of linkages could serve as a
quality control mechanism to reduce the emergence of DI genomes despite the ability of NS3-
5A to function in trans. In this regard, deletions in the NS3–5B region have not been observed
in naturally occurring HCV deletion mutants [55,113–115].
Given that both NS5A and NS5B are targets of HCV-specific antivirals [23,116], our find-
ings may have implications for the emergence of drug resistance. We predict that NS5A inhibi-
tors like DCVmay have synergistic effects when combined with inhibitors of the viral
polymerase. Furthermore, the barrier for resistance to drugs targeting NS5A and NS5B may be
high because replicase-expressed NS5B does not complement in trans and is linked to the
daclatasvir-sensitive activity of upstream NS5A; thus resistant alleles would need to arise with-
in the same genome. It is notable that DCV and sofosbuvir combination therapy shows high
rates of sustained virological response in HCV-infected patients [117].
The cis and trans activities of NS3-4A
Defects in the essential NS3 serine protease, RNA binding, and NTPase active sites were not
trans-complemented. This phenotype was not unexpected for the serine protease mutants,
which express uncleaved, inactive NS3–5B polyproteins (Fig 3G). These data suggest that a
protease inhibitor-sensitive virus would not be trans-complemented by an inhibitor-resistant
virus in vivo. Defects in the NS3 RNA binding and NTPase activities also were not comple-
mented in trans. We excluded nonspecific effects caused by instability of the mutant NS3 pro-
teins or disruption of underlying cis-acting RNA structures within this region of the viral
genome. Our data are most consistent with a requirement for the HCV NS3 RNA binding and
NTPase activities in cis. Similarly, for other Flaviviridae, the BVDV-1 NS3 NTPase active site
residues are required in cis [13,118], whereas a West Nile virus NS3 helicase mutant was trans-
complemented with very low efficiency [14].
Surprisingly the 3m5 mutant, which contained a lethal W501A mutation of a helicase
“bookend” residue, was complemented in trans. The NS3W501 residue has a key role in RNA
unwinding. Structurally, W501 stacks against the 3'-most base of RNA and DNA template
strands and may keep the template in register for up to three single-nucleotide translocation
steps [72,74,76]. In vitro, NS3 proteins containing the W501A mutation retain RNA binding
and NTPase activities [73,75,119]; such mutants have defects in RNA unwinding but can un-
wind DNA [75,77]. Thus, the NS3W501A mutant, SGR/Gluc(3m5), has basal helicase activity
but likely has a defect in processivity on RNA templates. While it has been established that
HCV helicase activity is required for RNA replication [34,35], the function of the helicase has
been unclear, including whether it binds to or unwinds viral RNA during replication. Given
that post-translational cis-preferences rely on protein-RNA interaction (Fig 8C), our data sug-
gest that the RNA binding and NTPase activities, but not RNA unwinding activity, contribute
to RNA template recruitment (Fig 3H). Remarkably, the RNA helicase/NTPase of brome mo-
saic virus also recruits viral RNA into membrane-bound replication complexes [120]. Thus,
RNA template recruitment may be a conserved function of positive-strand RNA virus-
encoded helicases.
Defects in the NS3 linker domain and NS4A C-terminal acidic domain also were comple-
mented, both by recoded NS3–5B and by replicons. The NS3 linker domain, which is con-
served and essential for RNA replication, coordinates interaction between the protease and
helicase domains and may mediate protein-protein interaction via a putative SH3-binding
motif [78]. The NS4A acidic domain contributes to helicase activity by promoting RNA-
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coupled ATP hydrolysis [37] and affects interactions with downstream NS4B and NS5A pro-
teins [65,79]. The helicase activity of recombinant NS3-4A protein containing the 4Am1 muta-
tion (NS4A Y45A) has efficient basal RNA-binding activity, but severely reduced ATP-coupled
RNA binding, RNA-stimulated ATPase activity, and RNA unwinding [37]. Thus, the 4Am1
mutant independently confirms that RNA unwinding activity of the NS3-4A helicase can be
supplied in trans.
Based on the ability to complement representative defects in NS3, NS4A, NS4B, NS5A, and
NS5B, we conducted a detailed complementation group analysis for the HCV NS3–5B genes.
These experiments revealed functional interactions between NS3-4A and NS4B: 3m6- and
4Am1-mutant replicons were trans-complemented less efficiently in cells expressing the
4Bm1-mutant form of NS3–5B, whereas 4Am1- and 4Bm1-mutant replicons were trans-com-
plemented less efficiently in cells expressing the 3m6-mutant form of NS3–5B. One interpreta-
tion of these data is that NS3-4A and NS4B preferentially interact with each other from the
same polyprotein (Fig 6G). Given that the NS3-4A-4B complementation grouping was recipro-
cal, it was surprising that 3m6- and 4Bm1-mutant replicons replicated well on cells expressing
the 4Am1-mutant form of NS3–5B. Furthermore, it was surprising that NS3 and NS4A activi-
ties segregated independently given that proteolytic processing of the NS3/NS4A junction is
autocatalytic [121] and is predicted to lead to cis-preferential interaction between NS3 and
NS4A [122]. One possible explanation is that NS3-4A dimerizes, such that one monomer pro-
vides NS3 activity while the other provides NS4A activity (Fig 8H). Indeed, we recently demon-
strated that the NS4A transmembrane domain mediates homodimerization that is essential for
RNA replication [80]. Alternatively, a second explanation might be that NS3-4A heterodimers
exchange partners to form a single fully active NS3-4A heterodimer (Fig 8H).
Complete replication in trans
We were able to complement an HCV SGR containing loss-of-function mutations in every rep-
lication gene (Fig 5E). It is notable that a few HCV “minigenome” systems have been developed
[123–127]. HCV minigenomes are RNAs encoding a reporter gene flanked by the HCV 5' and
3' noncoding regions; because they lack NS protein expression, minigenomes are presumably
replicated in trans by HCV replicons or NS3–5B transgene expression. Given the cis-require-
ments of NS3 and NS5B described here, it is surprising that minigenomes can be replicated in
trans. However, minigenome replication levels have not been compared directly to replicon or
infectious virus replication levels, nor has their sensitivity to HCV-specific antiviral com-
pounds been demonstrated. A key feature of these systems is that minigenome RNAs are pro-
duced continuously through transcription of transfected cDNA; hence they may represent a
single round of RNA synthesis rather than bona fide RNA replication and amplification. In this
regard, NS5B is capable of nonspecific RNA synthesis, in the absence of other HCV NS pro-
teins, when overexpressed in cell culture [128,129]. In contrast, the trans-replication system we
describe here supports authentic, long-term replication of defective HCV replicons initiated by
RNA transfection.
Conclusions
In summary, we have identified several cis- and trans-acting activities of the HCV NS3–5B
genes that are essential for RNA replication, including a non-enzymatic, cis-acting role of
NS5B in replicase assembly, and that NS3 RNA binding and NTPase activities are likely in-
volved in template recruitment. NS3-4A and NS4B activities co-segregated in complementa-
tion group analysis, whereas NS5B activity was dependent on the function of upstream NS3-
5A genes. Together, these studies reveal a network of functional interactions that could serve as
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a quality control mechanism for the HCV replicase genes and can be exploited by combination
therapies targeting multiple NS protein activities.
Materials and Methods
cDNA constructs and RNA transcription
SGR-Gluc was previously described as pYSGR-JFH/Gluc [65]. The noncytopathic VEEV vec-
tor 5'VEEVrep/L/GFP/Pac [84], a kind gift of Dr. Ilya Frolov (University of Alabama, Birming-
ham), was modified to replace the GFP insert with a short multi-cloning site. Briefly, oligos
YO-0779 and YO-0780 (S1 Table) were annealed and ligated into the XbaI/BsrGI sites of
p5'VEEVrep/L/GFP/Pac to yield pVEEV/MCS.
The JFH-1 NS3–5B region was recoded by GeneArt (Regensburg, Germany) to optimize
human codon usage, minimize RNA structure, and remove repeat sequences, RNA instability
motifs, and AT-rich or GC-rich sequences (S1 Text). The recoded NS3–5B region was sub-
cloned as a 6066-bp PacI/Ecl136II fragment into pVEEV/MCS cut with PacI and PmeI.
pJc1-Gluc(3–5Arc) was created by subcloning the SpeI/BstEII fragment of recoded NS3–5B
into pJc1-Gluc2A [96]. To make pSGR-Gluc(5Brc), a recoded NS5B–HCV 3' end (S3 Text)
was synthesized by Blue Heron Biotech (Bothell, WA) and cloned into pSGR-Gluc as a BsrGI/
XbaI fragment. pSGR-Gluc(5Bfs) was constructed by cleaving pSGR-Gluc(NS5Brc) with
BsrGI, fill-in with dNTPs and Klenow enzyme, followed by religation. pJc1-Gluc(3–5Arc) was
constructed by subcloning a SpeI/BstEII fragment from the recoded NS3–5B region into pJc1/
Gluc2A [96].
Mutations were introduced into SGR-Gluc or VEEV/NS3–5B by site-directed mutagenesis
with appropriate primer pairs (S1 Table). SGR-Gluc(5Bm1) was described previously as
pYSGR-JFH/Gluc(GNN) [65]. SGR-Gluc(4Am1) was constructed by subcloning the NS4A
Y45A mutation from Jc1/Gluc2A (NS4A Y45A) [65]. The recoded Met-NS5B gene was created
via PCR by using primers YO-0913 and YO-0908. The recoded Ubi-NS5B gene was con-
structed by overlap extension PCR with primers YO-0905, YO-0906, YO-0907, and YO-0908.
VEEV/NS3-5B is a large (16.6-kb) high copy number plasmid, and cloning efficiency was
improved by using high capacity E. coli strains such as XL10-Gold (Agilent). In contrast, we
were unable to obtain a VEEV vector expressing an unrecoded NS3-5B cassette (to test whether
the recoding process itself enabled trans-complementation) despite numerous cloning attempts
with several bacterial host strains. Given that the recoded NS3-5B cassette was successfully sub-
cloned into the VEEV vector several times, we suspect that the authentic JFH-1 NS3-5B se-
quence adversely impacted stability of the pVEEV plasmid. Nevertheless, the recoded NS3–5B
region functioned in trans and was used for our studies.
All constructs were confirmed by restriction digestion and/or Sanger sequencing. The se-
quence of all DNA segments that were amplified in vitro were confirmed and subcloned. HCV
RNA and VEEV transcripts were produced as previously described [87,130]. RNA transcripts
were treated with DNase I (Ambion) and purified with the Qiagen RNeasy kit with on-column
DNase digestion [130]. RNA concentrations were checked by spectrophotometry, adjusted to
100 ng/μl, RNA integrity was checked by agarose gel electrophoresis, and 10 μl aliquots were
stored at—80°C.
Cell culture and RNA transfection
Huh-7.5 human hepatoma cells were maintained in complete growth medium (Dulbecco’s
modified Eagle medium (DMEM; Invitrogen) containing 10% heat-inactivated fetal calf serum
(Omega Scientific) and 0.1 mM non-essential amino acids (Invitrogen)). Cells were transfected
with VEEV RNAs by electroporation as described [130]. Two days after electroporation,
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transfected cells were selected in complete growth medium containing 5 μg/ml puromycin
(Invivogen), passaged 3 to 4 times, then frozen. Thawed cells were maintained in puromycin-
containing complete growth medium and used within 4 or 5 passages; cells were seeded for ex-
periments in complete growth medium lacking puromycin. Cells were transfected with HCV
replicons by using 1 μl RNA and the TransIT mRNA transfection reagent (Mirus) according to
the manufacturer’s instructions. DCV was a kind gift of Mingjun Huang (Achillion Pharma-
ceuticals). For selection of stable replicon-bearing cells, the cells were transfected, as above, in
10 cm dishes. At two days post-transfection, the medium was changed to complete growth me-
dium containing 1 mg/ml G418 (Invitrogen) and selected for 3 weeks with triweekly media
changes. Colonies were fixed with methanol and stained with crystal violet [79].
Luciferase assays
At each time point, media were collected, cells were washed three times with phosphate buff-
ered saline, and fresh media was added. The collected media were clarified by centrifugation
(5 min at 21,130 x g), placed into fresh tubes, mixed with 1/4 volume 5x Lysis buffer (Promega
or NEB), and stored frozen (-80°C). Samples were assayed for Gluc activity on a Berthold Cen-
tro LB 960 plate reader [96] or a Berthold Centro XS3 LB 960.
Protein analysis
Cell lysates were prepared and equal amounts of protein were electrophoresed by SDS-PAGE,
transferred to polyvinylidene difluoride membranes and immunoblotted with NS3-specific
monoclonal antibodies 9G2 (Virogen) or 4E11 (this study), NS5A-specific monoclonal anti-
body 9E10 [130], NS5B-specific monoclonal antibody 5D1 (BioFront), or ß-actin-specific
monoclonal antibody AC-15 (Sigma) antibodies. We noticed that the NS5B-specific antibody
5D1 had large lot-to-lot variability in NS5B reactivity and non-specific background. Protein
masses were estimated based on the migration of the SuperSignal Enhanced Molecular Weight
protein ladder (Pierce, Rockford IL). To analyze polyprotein expression of defective replicons,
the vaccinia-T7 RNA polymerase expression system was used [131]. Briefly, Huh-7.5 cells were
seeded at 5 x 105/well into six-well plates the day before use. Cells were infected for 1 h at a
multiplicity of infection (MOI) of 10 with vTF7-3 and transfected with pSGR-Gluc derivatives
by using Mirus LT1 reagent according to the manufacturer’s recommendations. Lysates were
collected at 24 h post-transfection. Relative NS3 expression (Fig 3D) was quantitated by using
the gel analyzer densitometry feature of NIH ImageJ [132].
NS3 antibody production
Recombinant HCV NS3 protein was expressed and purified from E. coli as described [133].
BALB/c mice were primed and boosted at 3-week intervals with 25 μg recombinant NS3 pro-
tein complexed with adjuvant (RIBI Immunochemical). Approximately 1 month after the last
boost, sera were harvested and tested for immunoreactivity against HCV-infected Huh-7.5
cells. Mice with high titers (specific signal at>1/1,000 dilution) were boosted intravenously
with 15 μg purified NS3 protein in PBS. Splenocytes were harvested 3 d later and fused to
P3X63Ag8.653 myeloma cells to generate hybridomas according to published procedures
[134]. A total of 8 hybridomas were derived after repeated subcloning, and monoclonal anti-
bodies were purified by standard protein A/protein G chromatography. Monoclonal antibody
4D11 was found to react with NS3 protein by western blot of HCV-infected cells vs. uninfected
control cells. Other monoclonal antibodies developed in these fusions will be described
elsewhere.
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RNA analysis
RNA was harvested by using Trizol reagent (Invitrogen). For sequence analysis, HCV RNA
was amplified from the selected cell populations by RT-PCR and amplicons were directly sub-
mitted for Sanger sequencing; PCR products were also cloned into pCR2.1TOPO (Invitrogen)
and multiple independent cDNA clones were sequenced. HCV RNA was quantitated by
qRT-PCR as previously described [96] and normalized to total RNA concentration. Briefly,
2 μl of each RNA were assayed in 20 μl reactions containing 200 nM of an HCV IRES-specific
hydrolysis probe (6FAM-5'-TAT GAG TGT CGT GCA GCC TC-3'-MGBNFQ), 400 nM for-
ward (5'-CTT CAC GCA GAA AGC GTC TA-3'), 400 nM reverse (5'-CAA GCA CCC TAT
CAG GCA GT-3') primers, and the LightCycler RNA Amplification Kit (Roche). Reactions
were analyzed in a Roche LightCycler 480 by using a 45 minute RT step at 56°C, a 5 minute de-
naturation step at 94°C, followed by 40 cycles of denaturation (10 seconds at 95°C), annealing
(20 seconds at 60°C), and extension (3 seconds at 72°C). Quantitation curves were constructed
by analyzing HCV RNA standards in parallel [96].
Statistical analysis
All transfection experiments were performed at least twice, with each experiment containing at
least three replicate cell cultures that were independently plated, transfected, sampled, and ana-
lyzed. Mean relative light unit (RLU) values were calculated ± standard deviations (SD) based
on replicate data and plotted against matched control samples collected in parallel. Because
many samples could be processed in parallel, the same positive and negative controls are pre-
sented across multiple samples within large experiments, as explicitly noted in the
Figure legends. Because the background sensitivity of luciferase assays was affected by the lysis
buffer and luminometer hardware, data were normalized to untransfected cells by dividing the
mean value of each sample by the mean value from matched, mock-transfected cells collected
in parallel. To calculate SD values for the normalized data, the propagations of error were ac-
counted for as described [135]. Statistical significance was calculated in GraphPad Prism by
using two-tailed, paired Student’s t-tests of the normalized, replicate data for each time point.
Supporting Information
S1 Fig. NS5B trans-complementation. (A) SGR-Gluc(5Bm1) does not replicate in Huh-7.5
[VEE/NS3-5B(5Bm1)] cells, indicating that the NS5B active site is required in trans. (B)
SGR-Gluc(5Bm1) is not complemented by expression of NS5B alone via VEE/Met-NS5B or
VEE/Ubi-NS5B. (C) Western blot confirms that Ubi-NS5B is cleaved, presumably by a ubiquitin
C-terminal hydrolase, to produce full-length NS5B. (D) Complementation of full-length HCV
reporter virus Jc1/Gluc2A(5Bm1) in Huh-7.5[VEE/NS3-5B] cells. All values represent
mean ± SD from transfections performed in triplicate and normalized to untransfected controls;
experiments were repeated three times with similar results. (E) Sanger sequencing of trans-com-
plemented SGR-Neo(5Bm1) after three weeks of G418 selection and two weeks of additional
passage. Total RNA was extracted from G418-resistant cells with Trizol reagent, HCV-specific
cDNA was synthesized, the NS5B gene region was amplified by RT-PCR, and the PCR product
was directly sequenced. For comparison, a parallel sequence of VEE/NS3-5B DNA is shown.
(PDF)
S2 Fig. Supplementary data for NS3-4A complementation. (A) Secondary structure predic-
tion of the SGR-Gluc NS3 gene was calculated by mfold and represented here in a circle plot.
The NS3 gene is represented in a clockwise direction starting at 6 o’clock, with key residues and
residue numbers indicated around the circle. Arcs within the circle indicate predicted base pairs
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and are colored by pnum values, as indicated by the color scale. (B) Secondary structure predic-
tion of the SGR-Gluc (3–5Arc) NS3 gene, as in (A). (C) SGR-Gluc(3m7) and SGR-Gluc(4Am2)
replicate in Huh-7.5[VEEV/NS3-5B] cells but not Huh-7.5[VEEV/GFP] cells. Values represent
mean ± SD from transfections done in triplicate and normalized to untransfected controls.
(PDF)
S3 Fig. Complementation of NS4B and NS5A. (A and C) The replication of SGR-Gluc
(4Bm1) was tested in the indicated cell lines in parallel with the experiment shown in Fig 4A
and 4B. The replication of SGR-Gluc was reproduced from Fig 4 for comparison. (B andD)
The replication of SGR-Gluc(5A1) was tested in the indicated cell lines, as above. Values repre-
sent mean ± SD from transfections performed in triplicate and normalized to untransfected
controls. All experiments were repeated three times with similar results.
(PDF)
S4 Fig. The combined mutants are not trans-complemented by SGR-Neo. (A) The replica-
tion of SGR-Neo(3&5Bm) was tested in Huh-7.5 or Huh-7.5[SGR-Neo] cells. (B) The replica-
tion of SGR-Neo(4A–5Am) was tested in Huh-7.5 or Huh-7.5[SGR-Neo] cells. (C) The
replication of SGR-Neo(3–5Bm) was tested in Huh-7.5 or Huh-7.5[SGR-Neo] cells. Data were
plotted as in Fig 1B. The replication of SGR-Gluc in Huh-7.5 cells, performed in parallel, is
shown for comparison. Values represent mean ± SD from transfections performed in triplicate
and normalized to untransfected controls. All experiments were repeated three times with
similar results.
(PDF)
S1 Table. Primers used in these studies.
(DOCX)
S1 Text. Sequence of recoded NS3-5B.
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S2 Text. Sequence of NS5Brc. The NS5B gene begins at position 6013 in SGR-Gluc. The re-
gion downstream of the BsrGI site was recoded with silent mutations (lower case bp) to remove
stop codons from the -1 reading frame. SGR-Gluc(NS5Bfs) was constructed by cutting
SGR-Gluc(NS5Brc) BsrGI, refilling to form blunt ends, and religation.
(DOCX)
S3 Text. Sequence of NS3rc. The wild-type JFH-1 NS3 gene (WT) was aligned to the NS3rc
gene (RC), which contains recoded NS3 sequence downstream of SpeI. Mismatches are indicat-
ed by hash marks. The T269, D290, D291, and W501 residues are highlighted for emphasis.
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